Who are you looking for?

Install Famoose

Keep Famoose on your home screen or desktop for easy access.

Open this site in Chrome or Edge and look for Install app in the browser menu or address bar. If no install option appears, you can bookmark Famoose instead.

Famoose.co
Appearance
Text size
Page width
Colour
mRNA vaccine development

mRNA COVID-19 vaccine development

Earlier RNA and delivery research enabled rapid development of mRNA vaccines against COVID-19.

When
2020, building on decades of research
Where
International research, trials and manufacturing
A Pfizer–BioNTech COVID-19 vaccine vial.
A Pfizer–BioNTech COVID-19 vaccine vial.

Earlier RNA and delivery research enabled rapid development of mRNA vaccines against COVID-19.

01

Background

The groundwork preceded the emergency

Researchers had long explored using messenger RNA to instruct cells to produce a chosen protein. Obstacles included inflammatory responses, instability and effective delivery. Katalin Karikó and Drew Weissman's work on modified nucleosides addressed an important part of this problem, alongside many other teams' contributions.[2]

02

What happened

  1. 2005–2010

    Making RNA more usable

    Studies showed that modifying RNA bases could reduce unwanted innate immune activation and improve protein production. These findings helped make therapeutic and vaccine applications more practical. They were enabling discoveries, not a complete COVID-19 vaccine created years before the virus emerged.[2]

  2. 2020

    Design, trials and authorisation

    After the SARS-CoV-2 sequence became available, teams developed vaccines encoding its spike protein. Large trials and accelerated manufacturing supported the first authorisations late in 2020. The speed depended on earlier research and resources mobilised in parallel, not the absence of testing.[1]

03

Impact & evidence

A new platform reaches mass use

An important but collective achievement

The vaccines showed that mRNA could be deployed at extraordinary scale. Modified RNA, lipid delivery systems, antigen design, clinical research and manufacturing all contributed. The 2023 Nobel Prize recognised one foundational contribution rather than assigning sole authorship of the entire platform.[3]

04

Aftermath & legacy

Distribution shaped the outcome

Cold-chain requirements, production capacity and unequal access affected who benefited first. Protection also had to be studied as the virus evolved. The historical breakthrough is the platform's successful deployment, not a claim that vaccination alone ended the pandemic.[1]

Sources & image credits (3)
  1. Wikipedia — COVID-19 vaccine ↗
  2. Nobel Committee: scientific background to the 2023 medicine prize ↗
  3. Nobel Committee: explanation of the RNA modification discoveries ↗

Arne Müseler Image source ↗

Related historical cases